Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 46.245 -0.615 (-1.31%) Market Cap: 3.65 Bil Enterprise Value: 2.85 Bil PE Ratio: 0 PB Ratio: 4.15 GF Score: 35/100

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 09:30PM GMT
Release Date Price: $14.12 (-2.82%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Hey, good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. And we're continuing the 2021 Healthcare Conference today with Crinetics. Things are a little different this year, so instead of going across the hall to the breakout room after the presentation, you can ask questions by using that blue, Ask A Question button on your screen. That'll submit them to me on the portal, and I can ask management during the Q&A session. So without any further delay, let me turn it over to Crinetics CEO, Scott Struthers.

R. Scott Struthers
Crinetics Pharmaceuticals, Inc. - Founder, President, CEO & Director

Thanks, Jess. Thanks for the invite, and thanks to everybody listening. I'm here with Alan Krasner, our Chief Medical Officer; Gina Ford, our VP of Commercial Planning; and Marc Wilson, our CFO, who can help answer questions at the end of the talk portion.

I'll refer you to our forward-looking statements. Crinetics, as a reminder, is, in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot